Welcome to our dedicated page for JANUS LIVING news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JANUS LIVING stock.
Janus Living, Inc. reports developments as a pure-play senior housing real estate investment trust focused on senior housing communities across the United States. Company news centers on quarterly operating results, same-store revenue, occupancy and RevPOR trends, dividend declarations, liquidity actions, acquisition and investment activity, and the use of proceeds from its completed initial public offering.
Recurring updates also address Janus Living’s Class A-1 common stock trading on the New York Stock Exchange, its external management relationship with Healthpeak Properties, and capital resources such as unsecured revolving credit and term loan facilities used for general corporate purposes and portfolio growth.
JanOne (Nasdaq: JAN), represented by Dr. Amol Soin, will present at the Appalachian Region Spine and Pain Meeting on April 15, 2023, discussing innovation in pain medicine and the company’s drug development programs. JanOne focuses on non-opioid treatments for pain management, introducing two late-stage drug candidates: JAN 101, aimed at treating peripheral artery disease and diabetic neuropathy, and JAN 123, a low-dose naltrexone for Complex Regional Pain Syndrome, which received orphan drug status from the FDA. Dr. Soin aims to highlight the need for effective pain management solutions amid the opioid crisis, which underscores JanOne's commitment to developing non-addictive medication options. The meeting will serve as a platform to engage physicians seeking alternatives to opioids.
JanOne, a biopharmaceutical company on Nasdaq (JAN), announced the appointment of John N. Bonfiglio, PhD, as the interim president of its subsidiary, JanOne Biotech. His extensive background in leading successful biotech firms includes raising over $50 million for clinical trials at Immune Response Corporation. Bonfiglio aims to enhance JanOne's pain management solutions for conditions like diabetic neuropathy and Peripheral Artery Disease (PAD). CEO Tony Isaac expressed optimism for Bonfiglio's contributions to the company. The release also includes forward-looking statements which highlight potential developments while cautioning about related risks.
JanOne (Nasdaq: JAN), a biopharmaceutical company focused on non-addicting pain treatments, has entered a definitive securities purchase agreement to sell 361,000 common shares at $1.17 each in a registered direct offering. The anticipated gross proceeds are approximately $422,000, expected to close around March 24, 2023. Funds will support working capital and corporate purposes. The offering falls under a "shelf" registration statement effective since December 29, 2020. H.C. Wainwright & Co. is the exclusive placement agent.
On March 9, 2023, JanOne (NASDAQ: JAN) entered a Stock Purchase Agreement with VM7, resulting in the sale of its subsidiaries, ARCA Recycling, Customer Connexx LLC, and ARCA Canada Inc. This transaction reduced JanOne's liabilities by $17.6 million and ensures future payments of at least $24 million. The sale allows JanOne to focus on its biopharmaceutical endeavors, which aim to develop non-addicting pain relief treatments. CEO Tony Isaac expressed optimism about the company's growth potential in therapeutics following this strategic divestiture.
JanOne (NASDAQ: JAN) is set to showcase its research at the upcoming ASIPP annual meeting in March 2023. The company will present findings from the Phase IIa trial of JAN 101 for painful diabetic peripheral neuropathy and data from in vitro studies of JAN 123, a low-dose naltrexone for complex regional pain syndrome. Notably, JAN 123 has been selected as a finalist for the Society's 'Best Research Abstract of the Year'. Dr. Amol Soin emphasized the honor of being recognized for their innovative approach to pain treatment, aiming to help patients avoid addictive opioids.
JanOne (NASDAQ: JAN) held strategic meetings at Nasdaq MarketSite to review its drug development programs targeting the opioid crisis with non-addictive pain relief solutions. Two late-stage clinical programs include JAN 123, for complex regional pain syndrome, and JAN 101, for peripheral artery disease, both nearing FDA trials. The company's efforts are underscored by the pressing need for alternatives given the CDC's report of over 110,000 overdose deaths linked to opioids. Integration of Soin Therapeutics aims to enhance development capabilities, with leadership from Dr. Amol Soin, inventor of JAN 123, emphasizing a commitment to safer pain management solutions.
Summary not available.
JanOne Inc. (Nasdaq: JAN) has announced its acquisition of Soin Therapeutics LLC, valued at $13 million, with an additional $17 million contingent on revenue from a new product named Jan123. This product, a low dose naltrexone formulation, aims to treat Complex Regional Pain Syndrome (CRPS), a chronic pain condition without effective treatments. JanOne plans to advance Jan123 into clinical trials in 2023. This acquisition adds a significant clinical asset to JanOne's portfolio, complementing its existing product, JAN101, for Peripheral Artery Disease.
ARCA Recycling, a subsidiary of JanOne, has unveiled a new logo and website to reflect its commitment to innovative and environmentally responsible services. In the past year, ARCA recycled over 140,000 appliances, reducing carbon emissions by 136,600 metric tons. The new website features enhanced functionality for better user experience. ARCA aims to diversify its customer base while maintaining its core mission of energy efficiency and environmental protection. The branding update aligns with ARCA's expansion of appliance recycling services and underscores its dedication to a sustainable future.
JanOne Inc. (Nasdaq: JAN) announced an improved formulation of JAN101, developed by Dr. Maureen Donovan at the University of Iowa. This drug targets peripheral artery disease (PAD), affecting over 8.5 million in the U.S. Successful clinical trials demonstrated pain reduction and nerve function improvement. The new formulation aims to further enhance these benefits and will be used in upcoming pivotal clinical trials, with manufacturing by CoreRx set to begin soon.